Peters 2000.

Study characteristics
Methods	RCT
Participants	Country: USA Enrolled 268 patients, stage IA2, IB or IIA Underwent radical hysterectomy and pelvic lymphadenectomy. Ineligible 15 Assessed 243 (91%)
Interventions	Chemotherapy plus radiotherapy versus radiotherapy Arm 1: chemotherapy began on day 1 of radiotherapy and consisted of cisplatin 70 mg/m2 by 2‐hour intravenous infusion given on day 1 and 5‐FU 1000 mg/m2 per day given as a 96‐hour continuous infusion on days 1 to 4. The second cycle of chemotherapy began on day 22, and the third and fourth cycles of chemotherapy were scheduled after completion of radiotherapy, to begin on days 43 and 64. Arm 2: consisted of 1.7 Gy per day on days 1 to 5 each week, for a total of 29 fractions (49.3 Gy); pelvic radiotherapy was given to a standard four‐field box. Patients with positive high common iliac lymph nodes also received treatment to a para‐aortic field with a dose of 1.5 Gy per day on days 1 to 5 of each week, for a total of 30 fractions. The radiation source of treatment was 4MeV or more. Brachytherapy was not permitted.
Outcomes	Overall survival Progression‐free survival Grade 3/4 toxicity
Notes	Statistics on survival: Cox HR and P value. Kaplan‐Meier survival plots; minimum follow‐up estimated from dates of accrual and date of interim analysis. No. of deaths and disease recurrences by treatment arm. The estimated 4‐year survival was 81% for chemotherapy plus radiotherapy and 71% for radiotherapy only. The estimated 4‐year progression‐free survival for patients receiving chemotherapy plus radiotherapy was 80%, versus 63% for patients receiving radiotherapy alone. Median follow‐up: 42 months.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported, "Patients were randomised to either pelvic radiotherapy or pelvic radiotherapy with four cycles of chemotherapy".
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	For all survival outcomes: % analysed: 243/243 (100%) For toxicity: % analysed: 234/243 (96%) Chemotherapy + radiotherapy group: 122/127 (96%) Radiotherapy group: 112/116 (97%) "122 patients assessable for toxicity in the chemotherapy+ radiotherapy arm ... 112 patients randomised to RT alone and assessable for toxicity".
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	High risk	Based on an interim analysis of the data which rejected the null hypothesis of no benefit of chemotherapy.